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ABSTRACT
The prognostic potential of anti-tumor immune responses is becoming increasingly important in 
adenocarcinoma of the gastroesophageal junction and stomach (AGE/S) especially regarding the use 
of immune checkpoint inhibitors. This study analyzes for the first time the prognostic impact of 
tumor-infiltrating lymphocytes (TILs) and checkpoint inhibitors in a large Caucasian cohort in 
patients with AGE/S. We screened tissue samples from 438 therapy-naïve patients with AGE/S 
undergoing surgery between 1992 and 2005, examined in a tissue microarray (TMA) and stained 
against human CD3, CD4, CD8, PD-1, and PD-L1. Out of 438 tissue samples, 210 were eligible for 
multivariate analysis. This revealed that high infiltration with CD3+, CD4+, or CD8+ TILs was asso-
ciated with an increased overall survival in AGE/S patients, which could only be confirmed in 
multivariate analysis for CD3 (HR: 0.326; p = .023). Independent improved survival was limited to 
gastric cancer patients and to early tumor stages as long as TILs did not express PD-1 (HR: 1.522; 
p = .021). Subgroup analyses indicate that TIL-dependent anti-tumor immune response is only 
effective in gastric cancer patients in early stages of disease in PD-1 negative TILs. Combined 
analysis of PD-1 and CD3 could serve as a prognostic marker for the clinical outcome of gastric 
cancer patients and could also be of interest for immunotherapy.
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1. Introduction
Adenocarcinoma of the gastroesophageal junction and sto-
mach (AGE/S) represents the third most frequent tumor lead-
ing to death worldwide.1 While the incidence of 
adenocarcinoma of the stomach has been constantly decreas-
ing, mostly due to reclining Helicobacter pylori (HP) infections, 
the frequency of AGE is increasing in the Western world. This 
is thought to be driven by a rising incidence of obesity and 
consecutive reflux disease.2–4 The role of the immune system in 
tumor development and its role as a prognostic factor of the 
clinical course of gastric cancer and AGE/S are still controver-
sially discussed.5 On one hand, chronic inflammation due to 
HP-infection plays a significant role in gastric cancer develop-
ment. On the other hand, lymphocytic infiltration is associated 
with clinical outcome in various tumor entities.6 Expression of 
lymphocytes in tumor tissue correlates with an improved prog-
nosis in different types of tumors such as breast cancer, eso-
phageal squamous cell carcinoma, and colorectal cancer.7–9 
A study by Galon et al. in 2006 found a significant improve-
ment in survival in colorectal cancer patients with high lym-
phocyte infiltration in the tumor tissue.10 They especially 
differentiated between tumor margin and tumor center, 
which lead to an improved accuracy in prediction of survival 
and ultimately to the “Immunoscore ®”; however, prediction of 
benefit from adjuvant chemotherapy in stage II patients is 
missing.11
Tumor-infiltrating lymphocytes (TILs) have been investi-
gated in several studies for AGE and gastric cancer patients. 
Thus, a study from 2001 indicated, that a high infiltration with 
CD8+ lymphocytes is associated with a longer overall survival 
in a cohort of 70 patients with squamous cell and adenocarci-
noma of the esophagus.12
A meta-analysis from 2017 including 31 studies and 4185 
patients concerning the prognostic role of tumor-infiltrating 
lymphocytes (TILs) in gastric cancer identified a positive prog-
nostic value of a high infiltration with CD3+ and CD8+ lym-
phocytes, but not for CD4+ lymphocytes.13 The minority of 
patients with gastric cancer in this analysis was of Caucasian 
origin (13.0%) with a maximum sample size of 110 patients.
Microsatellite instability (MSI), as a marker for a deficient 
mismatch-repair (MMR) system, is a histopathological para-
meter with the promising association to clinical parameters.14 
An MSI-high status correlates significantly with improved sur-
vival as well as lower risk of relapse in colorectal cancer 
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patients, as stated in two meta-analyses including 71 studies in 
total.15,16 MSI status also seems to predict clinical benefit of 
immune checkpoint inhibition in this entity.17,18 The reason 
for this effect is the higher mutational burden caused by 
a deficient mismatch-repair system.18 A high mutational bur-
den leads to higher immunogenicity and therefore to a better 
response of immunotherapy.19 Microsatellite instability has 
also been found to be of prognostic importance in gastric 
cancer patients.20 A meta-analysis including 48 studies with 
a total of 18612 patients found a correlation between higher 
overall survival as well as lower tumor stages and MSI in gastric 
cancer.21 An exploratory analysis of the MAGIC trial showed 
that patients with MSI-high gastroesophageal or gastric cancer 
treated by surgery only had a significantly better prognosis, 
whereas MSI-high AGE/S patients who received perioperative 
chemotherapy showed worse overall survival.22
Recently, the T-cell inhibitory receptor PD-1 and its ligand 
PD-L1 came into the focus of research, as they play a central 
role in the functional suppression of T cell-dependent immune 
responses and the subsequent immune evasion of cancer 
cells.23 In different mice models by Lau et al., the absence of 
PD-L1 positive tumor cells improved the anti-tumor response 
of the host. PD-L1 deficiency in host immune cells led to 
a significantly higher rate of tumor regression with almost 
complete prevention of immunoevasion of the tumor.24 The 
inhibition of PD-1 is therefore not only realized by tumor cells 
expressing PD-L1 but also by TILs. The inhibition of PD-1 
targeting PD-1 and PD-L1 has evolved as a therapeutic option 
for the treatment of various tumor entities.25–27 However, the 
prognostic value of PD-1 and PD-L1 expression in TILs 
appears to vary between tumor entities. Thus, Darb-Esfahani 
et al. observed a positive correlation between the overall survi-
val of patients with ovarian cancer and a high expression of 
PD-1 and PD-L1 in TILs, whereas Thompson et al. described 
the opposite effect in renal cell carcinoma.28,29 In Caucasian 
gastric cancer patients, PD-L1 expression in TILs has been 
correlated with an increased survival in univariate, but only 
partly in multivariate analyses.30
Due to these contradictory data, we examined the prognos-
tic value of CD3+, CD4,+, and CD8+ TILs and PD-1 and PD-L1 
expression in tumor cells and TILs in a large, thoroughly 
characterized, therapy-naïve, Caucasian AGE/S cohort with 
respect to well-known clinical prognostic parameters including 
histology subtypes and clinical tumor stages.31
2. Materials and methods
2.1. Patients
Clinical data from patients with AGE/S of all tumor stages, 
with and without distant and lymph node metastasis and 
venous and lymphatic infiltration, primarily treated by sur-
gery between 1992 and 2004 at the Charité – 
Universitätsmedizin Berlin, Charité Campus Buch, were col-
lected retrospectively.
Overall survival was defined as time from diagnosis to death 
or last follow-up. Tumor-related survival was defined as time 
from diagnosis to tumor-related death or last follow-up. The 
data regarding patient characteristics and follow-up 
information were retrieved from the patient management soft-
ware (SAP®) and the regional population-based cancer registry 
(“Gemeinsames Krebsregister”). The study was approved by 
the Institutional Review Board of the Charité (EA4/115/10) 
and conducted accordingly.
2.2. Tissue samples
Tissue samples were collected from the archive of the Institute 
of Pathology, Charité- – Universitätsmedizin Berlin. Four hun-
dred thirty-eight samples of formalin-fixed and paraffin- 
embedded (FFPE) tissue were available of chemotherapy- 
naïve patients undergoing surgery. Tissue samples were reeval-
uated for postoperative histological diagnosis, tumor stage, 
grading, and were morphologically classified using the Laurén 
and Ming classification by a pathologist with a special focus on 
gastrointestinal pathology (M.W.). Additional data concerning 
tumor size, depth of invasion, and tumor invasion of veins or 
lymphatic vessels were obtained from the Charité – 
Universitätsmedizin Berlin patient management software.
2.3. Tissue microarray and immunohistochemistry
Tissue samples were screened using Hematoxylin- and Eosin- 
stained sections for representative areas of solid tumors. Two 
1 mm-diameter tissue cores were punched out of the central 
tumor region from each of the 438 available samples and 
transferred to a recipient paraffin block. After re-melting, sec-
tions (4 µm thick) were consecutively cut from each tissue 
microarray (TMA) block. Hematoxylin and Eosin staining 
was performed on TMA sections for reconfirmation of tumor 
and non-tumor tissue.
Only TMA cores that contained representative tumor sec-
tions were considered for subsequent analyses (Figure 1).
For checkpoint proteins PD-1 and PD-L1, automated 
immunohistochemistry was performed on 2 µm thick slides 
of paraffin-embedded tissue with Leica BOND-maxTM immu-
nostainer (Leica Microsystems) using the Bond Polymer Refine 
(a peroxidase-based detection reagent). The slides were coun-
terstained with Hematoxylin (Figure 2). For mismatch-repair 
proteins, immunohistochemistry was performed on an auto-
mated staining system (BenchMark Ultra, Roche Ventana, 
Germany) using prediluted antibodies. For a detailed version 
of the visualizing agents, see Table S1 in the supplement.
All cases were evaluated by two experts blinded to the 
patients’ clinical information visualized in one high power 
field in two cores per tumor sample. Representative areas 
from each core were chosen for TIL counting. Due to the 
procedure of cutting and staining, some samples could not be 
used for the evaluation. Samples with insufficiently representa-
tive tumor tissue were also excluded from the evaluation. The 
average of positive cells was calculated per square millimeter. 
The representativity of each core was jointly discussed and 
cases with diverging results were analyzed in detail. Detailed 
discussion was necessary in 62 cases for CD3, in 35 cases for 
CD4, and in 28 cases for CD8. PD-1 and PD-L1 were analyzed 
by two different experts using the CPS (combined positive 
score).
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2.4. Statistical analyses
Statistical analyses were performed using the IBM SPSS soft-
ware Version 24. Because TILs were not normally distributed, 
they were grouped in high and low by using the median, not 
the mean, as a cutoff. The examination of survival analysis for 
quartiles showed a gradual decrease in survival from a high TIL 
infiltration to a low TIL infiltration (see Figure S4). To simplify 
further analysis, we decided for binary categories by using the 
median for statistics. For PD-1 expression on immune cells, 
≥1% was used as a cutoff. For the interpretation of the PD-L1 
staining, the CPS (Combined Positive Score) with the cutoff ≥1 
was chosen. Quantitative values were expressed as mean± 
standard deviation, median, range, and categorical values 
with absolute and relative frequencies (count and percent). 
Overall survival was evaluated using Kaplan–Meier plots. 
Associations of CD3+, CD8+, and CD4+ densities with tumor 
size, distant and lymph node metastasis, venous and lymphatic 
infiltration, Laurén and Ming classification, grading, and UICC 
classification were tested using the chi-square-test (X2-test). 
Univariate survival analyses were performed according to the 
Figure 1. Immunohistological staining for CD3+, CD4+, and CD8+ cells in 400-fold magnification. Tumor samples were grouped into a low or high state of infiltration 
with CD3, CD4, or CD8 positive TILs by using the median.
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Kaplan–Meier method using log-rank test for the assessment of 
statistical significance. Cox regression was performed for mul-
tivariate analyses in a stepwise forward/backward selection 
with the level of significance set to p < .05. Due to a high 
correlation between CD3+, CD4+, and CD8+, we analyzed 
each factor in single cox-regression models.
Low CD3+, CD4+, or CD8+ TILs states served as an analy-
tical reference category in the multivariate analyses. For inter-
action analyses between CD3+, CD4+, and CD8+ TILs state and 
UICC stage, a low TILs state and UICC stage I and II were used 
as a reference category.
Reporting recommendations for tumor marker prognostic 




Data of 438 patients were collected for this study (female = 178, 
median age = 62 y) (95% CI: 60.97–63.15 y).
The detailed clinicopathological characteristics of our 
patient cohort are summarized in the supplement (see 
Figure 2. Immunohistochemical staining for PD-1 and PD-L1 expression in tumor cells and TILs in 400fold (b,d,e) and 20fold (a,c,f) magnification. Samples were grouped 
into negative or positive with a cutoff value of >1% expression or with CPS > 1.
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Supplement Tables S2, S3, and S4). The mean follow-up was 
121.7 months (95% CI: 113.9–129.5 months) and 291 patients 
(66.4%) died during follow-up time, 225 (51.4%) of those 
tumor-related. The 5-year overall survival was 38.1%, the 
5-year tumor-related survival was 45.4%.
3.2. MMR status
Deficient mismatch repair (dMMR) was shown in 45 patients 
(10.3%) using immunohistochemical staining against MSH2 
and MLH1, whereas 338 (77.2%) showed proficient mismatch 
repair (pMMR), in 55 patients (12.6%) MMR status was not 
evaluable. Mean survival was 47.22 months in dMMR patients 
and 79.78 months in pMMR patients (p = .025). In this AGE/S 
cohort, dMMR patients were diagnosed in higher tumor stages 
compared to pMMR patients (dMMR: T1/T2: 40% T3/T4: 60% 
vs pMMR: T1/T2: 62%, T3/T4: 38% (x2: p = .032); Figure S2). 
Stage-related overall survival analyses showed no significant 
differences in the survival of dMMR and pMMR patients.
3.3. CD3, CD4 and CD8 expression
The significance of TILs in AGE/S in Caucasian patients is yet 
to be examined in larger cohorts. In order to determine the 
prognostic value of TILs in AGE/S, the expression of CD3, 
CD4, and CD8 in TILs was determined in tumor tissue, but not 
in non-neoplastic gastric and esophageal tissue. Out of 438 
samples, 349 CD3, 335 CD4, and 344 CD8 stained samples 
were evaluable for the analysis. The analysis of the remaining 
samples was not possible due to missing representative tumor 
tissue in the respecting cores. Exemplary sample images of the 
analyzed IHC staining are shown in Figure 1. Examples for TIL 
count are shown in Figure S1 in the supplement.
The mean count of TILs/mm2 was 122 in the CD3 low 
group and 513 in the CD3 high group, 30 in the CD4 low 
group and 251 in the CD4 high group and 74 in the CD8 low 
group, and 360 in the CD8 high group. High/low status of CD3 
correlated strongly with the state of CD4 (p < .0001) and CD8 
(p < .0001).
Patients with a high CD3+ state showed a significantly 
increased mean overall survival in comparison to those with 
a low CD3 count (CD3: 106.04 months vs. 64.38 months; 
p = .002). The same effect could be detected for CD4+ and 
CD8+ (CD4: 116.91 months vs. 56.36 months; p < .001; CD8: 
101.53 months vs. 67.34 months; p = .016) (Figure 3(a); 
Supplementary Figure S3(a,b)).
Subgroup analyses showed that the positive prognostic 
effects of TIL infiltration were limited to UICC stage I. In 
higher tumor stages, these effects were no longer detectable 
or even opposed in UICC stage III (Table 1, Figure 3(c); 
Supplementary Figure S3(c,d)).
To recognize confounding and interacting parameters, 
a multivariate and interaction analysis was performed with all 
parameters that reached statistical significance in the univariate 
analysis. For multivariate analysis, only cases with evaluable 
staining for each included marker were used (n = 210). Due to 
the high correlation of CD3, CD4, and CD8 TIL state, these 
parameters were analyzed in separate cox-regression models. 
The multivariate analysis showed that a high CD3 state (CD3: 
HR: 0.326; p = .023) as well as the interaction between CD3+ 
state and UICC stage are independent prognostic factors, but 
only in the backward analysis (CD3*UICC: HR: 1.949; 
p = .004). The corresponding cox-regression models for high 
CD4 and CD8 infiltration showed neither significance for 
CD4+ or CD8+ cells nor significant interaction with UICC. 
Interaction between CD4+ lymphocytes and UICC stage did 
only reach statistical significance in backward, but not in the 
forward analysis (CD4*UICC: HR: 1.607; p = .044). All results 
of univariate and multivariate analysis are depicted in Table 2 
as well as in the supplements (Tables S4, S5).
3.4. PD-L1 and PD-1 expression
PD-L1 and PD-1 expression was analyzed in tumor cells and in 
TILs. In 328 cases (74.9%) staining could be evaluated.
Depending on the presence or absence of PD-L1 and PD-1, 
we separated the findings in lymphocytes and tumor cells into 
two groups: PD-L1 and PD-1 positive and negative.
3.4.1. PD-1
A significantly increased mean overall survival in univariate 
analysis was shown in the group with no PD-1 expression in 
TILs: neg: 95.07 months vs. pos: 56.51 months; p = .001 (Figure 
3(b)). PD-1 expression was strongly correlated to the state of 
CD3+ TILs. Among all tumors, 30.9% (n = 92) had a high CD3 
state and were PD-1 positive in TILs and 17.4% (n = 52) of 
those were PD-1 negative (x2: p < .001). The interaction 
between CD3 state and PD-1 expression in TILs also reached 
statistical significance in multivariate analysis, which makes it 
an independent prognostic marker (Figure 3(d)). The protec-
tive effect on overall survival of high CD3 state described above 
(see 3.2) was not detectable in patients with PD-1 expression in 
TILs (PD-1 pos: CD3 high vs low: 53.7 vs. 59.8 months p = .714; 
PD-1 neg: 132.6 vs 65.9 months, p = .001). The interaction 
between PD-1 expression and CD4 and CD8 state did not 
reach statistical significance (see Supplement Tables S4, S5). 
PD-1 expression in TILs was not significantly disbalanced over 
the UICC tumor stages (I: 41.1%, II 47.3%, III 64.4%, IV 51.2%; 
p = .066).
PD-1 expression in tumor cells was only measurable in 
UICC I tumor samples; high significant differences in overall 
survival between PD-1 positive and negative tumors were 
therefore caused by this disbalanced expression pattern over 
the tumor stages: PD-1: neg. 58.96 months vs. pos. 
175.79 months; p < .001. The positive prognostic effect of 
CD3 was not influenced by PD-L1 expression in tumor cells.
Due to the strong correlation to UICC stages, PD-1 expres-
sion in tumor cells was excluded from multivariate analyses.
3.4.2. PD-L1
The expression of PD-L1 in TILs showed no effect on overall 
survival (p = .428). PD-L1 expression in tumor cells was asso-
ciated with a significantly higher mean survival in univariate 
analysis: 119.56 months vs. 68.23 months, p = .003. This effect 
was not confirmed in multivariate analysis (HR: 0.848; p = .580). 
This might have been caused by the disbalanced distribution of 
PD-L1 positive tumor cells over the UICC stages in favor of 
early tumor stages (I: 25.7%, II: 6.3%, III: 6.5%, IV: 4.8%; 
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p < .0001). In the stage-dependent subgroup analysis, PD-L1 
expression in tumor cells had no effect on overall survival in any 
UICC stage. PD-L1 positive tumor cells were detectable in 6.3% 
(n = 10) of tumors with low CD3 state and in 17.2% (n = 25) 
with high CD3 state (x2 p < .003). The prognostic effect of CD3 
was not associated with PD-L1 state in tumor cells. All results of 
univariate and multivariate analysis are depicted in the supple-
ment (Tables S4, S5).
3.5. Localization
Tumors were localized in 84.9% (n = 372) in the stomach and 
in 15.1% at the gastroesophageal junction (n = 66). 
Figure 3. (a) Overall survival depending on high CD3 positive lymphocyte infiltration state. (b) Overall survival depending on PD-1 expression on tumor-infiltrating 
lymphocytes. (c) Overall survival depending on high CD3 positive lymphocyte infiltration state and UICC stage. (d) Overall survival depending on PD-1 expression on 
TILs and on CD3 positive lymphocyte infiltration state. (e) Overall survival depending on PD-1 expression in tumor-infiltrating lymphocytes and tumor localization. 
Tumor samples were grouped for low versus high infiltration with CD3 positive TILs by using the median. For grouping in PD-1 and PD-L1 positive/negative, an 
expression ≥1% was used as a cutoff.
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Distribution over tumor stages was well balanced (AGE: UICC 
I/II: 24.9% and III/V 22.9% p = .107). Localization did not 
influence median overall survival (AGE: 80.1 vs. stomach: 
84.0 month; p = .799). Furthermore, the localization did not 
influence the positive effect of CD3+ TILs on overall survival 
(AGE: CD3 low 74.1 vs. 109.1 month (p = .276); stomach: CD3 
low 63.3 vs high 104.8 months (p = .004)). The negative prog-
nostic effect of PD-1 expression in TILs could only be shown in 
the stomach subgroup (AGE: PD-1 TILs neg 65.5 vs 
70.0 months; p = .636); stomach: PD-1 TILs neg 98.9 vs 
54.3 months (p < .001) (Figure 3(e)).
4. Discussion
The impact of TILs concerning Caucasian patients with AGE/S 
still lacks a solid analysis, since only small cohorts have been 
investigated so far.12,33 Most existing data concern patients of 
Asian origin, which underlines the importance of our data in 
Caucasian patients.34,35 Our data showed that increased infiltra-
tion with CD3+ lymphocytes is an independent prognostic factor 
for increased overall survival in AGE/S patients in a large cohort 
with long follow-up data. With insight into subgroup analyses, 
this effect is however limited to early tumor stages. Thus, the 
positive prognostic effect of high TIL infiltration is restricted to 
tumors with PD-1 negative TILs. While the positive prognostic 
effect of CD3+ cell infiltration was independent from tumor 
localization, the negative prognostic influence of PD-1 expression 
in TILs could only be shown in gastric cancer patients. Our 
findings suggest that immune defense exerts a significant role 
for the overall survival in early stages of AGE/S and the expression 
of PD-1 in TILs may inhibit the anti-tumorous immune response.
The reason why the positive prognostic effect of TILs on 
prognosis is limited to early tumor stages in our study remains 
unclear. The concept of acquired resistance and tumor 
immune evasion via mechanisms like direct interaction 
through T-regulatory cells (Tregs) or T-cell exhaustion might 
be of importance.6,36 It has been stated in the past that the 
alteration of tumor reactivity toward TILs during tumor 
progression could be caused by an immunosuppressive net-
work in the tumor microenvironment.37
As already stated, a deficient MMR system improves prog-
nosis in gastric cancer patients.21 The reported higher response 
to immunotherapy caused by a higher immunogenicity in 
MSI-high tumors would be of high interest in this analysis. 
As opposed to existing data, patients in our study showed 
a significantly decreased overall survival with dMMR in uni-
variate analyses. This effect was caused by significantly lower 
tumor stages of pMMR patients. Because of this imbalance in 
our cohort with MMR status being strongly dependent on 
tumor stage, independent interaction between MMR status 
and prognostic relevance of TILs could not be examined.
Immune therapeutic approaches have successfully been 
integrated into therapeutic routine in several disease entities 
but results in AGE/S are still unsatisfactory.38–40 Studies con-
cerning the treatment of AGE/S tumors with checkpoint inhi-
bitor therapeutics such as Pembrolizumab are using PD-L1 as 
a single identification marker to evaluate the predictive 
value.40,41 These unsatisfactory results may occur, because 
patient selection and predictive markers are yet to be 
improved.42 This study indicates that PD-1 expression in cor-
relation to CD3+ TILs may influence the predictive value in 
a favorable way. Whilst overall survival significantly improved 
when CD3+ lymphocyte infiltration was high and TILs did not 
express PD-1, this effect on survival was not found when PD-1 
was expressed. This could indicate that patients with a high TIL 
state as well as a PD-1 expression in TILs in gastric cancer 
could significantly profit from checkpoint inhibitor therapy. 
This would concern 30.9% of patients in our study. This effect 
remains to be examined in further studies or could also be 
retrospectively evaluated in past studies.
There exist contradicting data about the association of PD- 
1/PD-L1 expression in AGE/S concerning the prognostic value 
on overall survival: whilst in accordance with our data several 
studies demonstrated a negative effect on overall survival, 43 
Böger et al. indicated a positive correlation with longer survival 
Table 1. Subgroup analyses: overall survival in months related to TIL infiltration state and UICC stage.
TILs high TILs low
OS (Month) OS (Month) p
CD3
UICC I 176.54 108.17 0.001
UICC II 57.77 79.86 0.341
UICC III 16.88 43.24 0.008
UICC IV 8.05 11.94 0.221
All 106.04 64.38 0.002
CD4
UICC I 170.72 116.83 0.022
UICC II 59.14 64.76 0.306
UICC III 16.82 36.44 0.038
UICC IV 8.05 11.94 0.221
All 116.91 56.36 <0.001
CD8
UICC I 168.74 118.41 0.042
UICC II 60.12 78.55 0.508
UICC III 26.0 28.15 0.644
UICC IV 9.9 11.33 0.789
All 101.53 67.34 0.016
Tumor samples were grouped for low or high infiltration with CD3+, CD4+, or CD8+ TILs by using the median. Differences in overall survival were compared by Kaplan 
Meier using log rank.
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in patients with high expression of PD-L1 in tumor and in 
immune cells in a large Caucasian cohort.30 A study by 
Thompson et al. indicated that the absence of PD-L1 positive 
tumor cells leads to improved overall survival in AGE/s 
patients.44 Wu et al. detected a positive prognostic effect of PD- 
L1 expression in TILs in gastric cancer patients.45 Because of an 
uneven distribution of PD-L1 expression throughout the UICC 
stages in our patient cohort, we could not reproduce these 
results.
The limitations of our study lay firstly in methodical issues 
concerning the Tissuemicroarray technique. By using this techni-
que, the evaluation of tumor tissue focuses on a distinct area of the 
tumor, which was chosen as representative for the tumor in its 
entirety. However, intratumoral heterogeneity as well as an 
uneven distribution of TILs throughout the tumor is clearly 
neglected by using this method and should be taken into con-
sideration when assessing these data.46 We were also unable to 
differentiate between invasive margin and tumor center, which 
Table 2. Univariate and multivariate survival analyses including CD3, CD4, CD8 positive infiltration state and PD-1 and PD-L1 positive infiltration state.
Univariate Multiple Cox Regression (after forward/[backward] selection)
Clinical Factor Mean Survival CI p HR CI p
Total patients 83.78 74.7–92.86
Age 
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CI: confidence interval; HR: hazard ratio. Multivariate analysis: n = 210. TILs were grouped into high or low by a median cutoff. Mean survival is shown in months of 
survival. All factors significant in univariate analysis were analyzed in a multivariate cox-regression model. The reference categories for multivariate analysis are “low 
infiltration” for CD3, CD4 and CD8, “low CD3 infiltration and UICC I + II” for interaction between CD3 and UICC stage, “low CD3 infiltration and PD-1 expression 
negative” for interaction between PD-1 expression and CD3, “patient age < 62 y” for age, “male” for sex, “positive” for MMR status, “UICC I” for UICC stage, “R0” for R, 
“negative” for PD-1 and PD-L1 and “intestinal type” for Laurén classification. CD4+ and CD8+ TILs infiltration as well as PD-1 infiltration in tumor cells were excluded 
from multivariate analysis due to high statistical correlation. 
* The resection state of the palliative cases was censored in multivariate confounder analysis, because of strong statistical interaction with UICC stage.
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plays a significant prognostic role according to Galon et al.10 
A considerable number of patients had to be excluded for survival 
analysis for different reasons, such as palliative surgery or uneva-
luable staining. Overall, we performed multivariate analysis in 210 
cases, which is still a large number for an AGE/S cohort. Lastly, we 
examined a cohort, which was treated between 1992 and 2005. 
These patients did not receive treatment by modern standards 
(e.g. perioperative chemotherapy), which makes it difficult to 
evaluate the data in these aspects. However, this gave us the 
opportunity to examine chemotherapy-naïve tumor tissue over 
all UICC stages, which allows better comparability.
Overall, we demonstrated a strong positive prognostic effect 
of CD3+ and PD-1 negative tumor-infiltrating lymphocytes in 
early tumor stages for gastric cancer patients in a large AGE/S 
patient cohort. Our study has strong advantages with a high 
patient number, positive statistics in univariate and multivari-
ate analyses, and a homogenous study population. In our 
cohort, the number of patients with early tumor stages is 
increased compared to other studies with Caucasian cohorts. 
This is certainly due to the retrospective design of the study. 
However, it is worth speculating that this increased patient 
number reached statistical significance to underline the role 
of the immune system in these tumor stages. Subgroup ana-
lyses based on immune cell infiltration could explain disap-
pointing effects of checkpoint inhibitors as seen, e.g. in the 
Keynote 028, 061, and 062 studies.38,40,47 Our data may help to 
identify high-risk groups in early tumor stages. The negative 
predictive value of the PD-1 expression in TILs could also be an 
indication that it can be of prognostic significance for evaluat-
ing the effectiveness of checkpoint inhibition.
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